WORLD'S LARGEST MARKET RESEARCH RESOURCE — 1,519,265 REPORTS

 
 
• SEARCH FOR A REPORT

Viewing report

Search
Enter keywords, a title or a report id number below.
Advanced

• ORDER BY FAX

Order By Fax

• SELECT SITE CURRENCY

Select a currency for use throughout the site



  • Electronic Information Icon
Live Chat Live Help Software for Website

Fresenius SE And Fresenius Medical Care Outlook Revised To Positive On Improved Debt Protection Metrics; 'BB' Rtgs Affmd Apr 10

Standard & Poors, April 2010

Abstract
Germany-based health care group Fresenius SE (FSE) and its subsidiary Fresenius Medical Care AG & Co. KGaA (FME) continue to deliver strong operating performance and improve their debt protection metrics. We are revising the outlook on both FSE and FME to positive from stable, and affirming the 'BB' long-term corporate credit ratings on both entities. The positive outlook reflects our view that both FSE and FME will continue to use their strong earnings to reduce debt leverage progressively over the short to medium term. LONDON (Standard & Poor's) April 29, 2010--Standard & Poor's Ratings Services said today that it revised the outlook on Germany-based health care group Fresenius SE (FSE) and its subsidiary Fresenius Medical Care AG & Co. KGaA...

Companies mentioned in this report are: Fresenius SE & Co. KGaA
Action: Affirmed
Action: Outlook: Positive

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Fresenius SE & Co. KGaA

Customers who bought this item also bought